Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APRENASDAQ:CALANASDAQ:CLSNNASDAQ:GRAYNASDAQ:PULM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$6.07+2.5%$6.36$2.78▼$8.85$22.12M1.0576,003 shs16,742 shsCALACalithera Biosciences$0.02$0.03$0.01▼$0.50$100K-0.17883 shs1,281 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsGRAYGraybug Vision$4.19+1.5%$4.83$5.00▼$22.12$6.58M1.22,165 shs1,242 shsPULMPulmatrix$1.63-3.6%$1.80$1.55▼$3.15$6.17M0.9511,288 shs11,761 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+2.53%-6.62%-15.10%+65.85%+31.67%CALACalithera Biosciences0.00%-20.16%-20.32%-33.33%-50.00%CLSNImunon0.00%0.00%0.00%0.00%0.00%GRAYGraybug Vision0.00%+21.10%-6.68%+44.48%-23.54%PULMPulmatrix-3.59%-1.07%-16.41%-15.98%-46.20%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics3.4362 of 5 stars3.53.00.00.02.83.31.3CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix2.7841 of 5 stars3.55.00.00.03.30.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics3.00Buy$15.50155.35% UpsideCALACalithera BiosciencesN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/APULMPulmatrix3.00Buy$10.00513.50% UpsideCurrent Analyst RatingsLatest CALA, PULM, GRAY, APRE, and CLSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.003/26/2024APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$580K39.14N/AN/A$9.66 per share0.63CALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.05CLSNImunon$500K0.00N/AN/A$9.66 per share0.00GRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/APULMPulmatrix$6.07M0.98N/AN/A$8.55 per share0.19Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$112.66M-$3.99N/AN/AN/AN/A-61.06%-49.57%5/20/2024 (Estimated)CALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/A3/29/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AGRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/APULMPulmatrix-$18.84M-$4.43N/A∞N/A-238.89%-64.09%-44.78%4/4/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A6.156.15CALACalithera BiosciencesN/AN/AN/ACLSNImunon0.136.526.52GRAYGraybug VisionN/A10.7310.72PULMPulmatrixN/A5.245.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CALACalithera BiosciencesN/ACLSNImunon12.97%GRAYGraybug Vision49.94%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics20.90%CALACalithera Biosciences6.60%CLSNImunon4.66%GRAYGraybug Vision7.94%PULMPulmatrix3.61%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics93.74 million2.96 millionNo DataCALACalithera Biosciences84.87 million4.55 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableGRAYGraybug Vision271.57 million20.25 millionNot OptionablePULMPulmatrix283.65 million3.52 millionNot OptionableCALA, PULM, GRAY, APRE, and CLSN HeadlinesSourceHeadlinePulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.comamericanbankingnews.com - March 23 at 2:16 AMCipla Ltd CIPLAmorningstar.com - February 15 at 11:00 PMGlobal deaths from fungal disease have doubled in a decade – new studytheconversation.com - January 13 at 7:42 AMFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersbizjournals.com - January 10 at 7:51 AMPulmatrix shuts down study, explores salebizjournals.com - January 9 at 3:43 PMPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Studynasdaq.com - January 8 at 1:11 PMPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternativesmarketwatch.com - January 8 at 1:11 PMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternativesfinance.yahoo.com - January 8 at 1:11 PMStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata Steelmsn.com - January 8 at 12:42 AMStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In Focusmsn.com - January 8 at 12:42 AMTrade Setup for Jan 8: IT earnings to be the Nifty 50's focal point this weekcnbctv18.com - January 7 at 9:11 AMPulmatrix Inc PULMmorningstar.com - November 12 at 9:08 AMPulmatrix Down on Q3 Resultsbaystreet.ca - November 9 at 1:38 PMPulmatrix GAAP EPS of -$1.03, revenue of $1.75Mmsn.com - November 9 at 1:38 PMPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 1:38 PMAspergillosis Treatment Research Report 2023finance.yahoo.com - October 23 at 3:27 PMPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100markets.businessinsider.com - September 19 at 9:49 AMPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migrainefinance.yahoo.com - September 19 at 9:49 AMPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowmsn.com - September 11 at 3:15 PMPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazolefinance.yahoo.com - August 23 at 6:11 PMPulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - August 10 at 2:43 PMPulmatrix GAAP EPS of -$1.04, revenue of $1.84Mmsn.com - August 10 at 2:43 PMPulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 9:42 AMPulmatrix seeks US FDA approval to to Initiate phase 2 trial of investigational drug PUR3100 to treat acute migrainepharmabiz.com - July 13 at 8:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?All In: Is MicroStrategy Overleveraging Its Future on Bitcoin? March 26, 2024 6:05 AMView All In: Is MicroStrategy Overleveraging Its Future on Bitcoin? All Headlines Company DescriptionsAprea TherapeuticsNASDAQ:APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Calithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Graybug VisionNASDAQ:GRAYGraybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.